Abstract
Background Although reports suggest that most individuals with COVID-19 develop detectable antibodies post infection, the kinetics, durability, and relative differences between IgM and IgG responses beyond the first few weeks after symptom onset remain poorly understood.
Methods Within a large, well-phenotyped, diverse, prospective cohort of subjects with and without SARS-CoV-2 PCR-confirmed infection and historical controls derived from cohorts with high prevalence of viral coinfections and samples taken during prior flu seasons, we measured SARS-CoV-2 serological responses (both IgG and IgM) using commercially available assays. We calculated sensitivity and specificity, relationship with disease severity and mapped the kinetics of antibody responses over time using generalised additive models.
Results We analysed 1,001 samples from 752 subjects, 327 with confirmed SARS-CoV-2 (29.7% with severe disease) spanning a period of 90 days from symptom onset. Sensitivity was lower (44.1-47.1%) early (<10 days) after symptom onset but increased to >80% after 10 days. IgM positivity increased earlier than IgG-targeted assays but positivity peaked between day 32 and 38 post onset of symptoms and declined thereafter, a dynamic that was confirmed when antibody levels were analysed, with more rapid decline observed with IgM. Early (<10 days) IgM but not IgG levels were significantly higher in those who subsequently developed severe disease (signal / cut-off 4.20 (0.75-17.93) versus 1.07 (0.21-5.46), P=0.048).
Conclusions This study suggests that post-infectious antibody responses in those with confirmed COVID-19 begin to decline relatively early post infection and suggests a potential role for higher IgM levels early in infection predicting subsequent disease severity.
Competing Interest Statement
Declarations of Interest: Patrick W. G. Mallon has received honoraria and/or travel grants from Gilead Sciences, MSD, Bristol Myers Squibb and ViiV Healthcare. Willard Tinago no conflicts declared. Alejandro Abner Garcia Leon no conflicts declared. Kathleen McCann no conflicts declared. Grace Kenny no conflicts declared. Padraig McGettrick no conflicts declared. Sandra Green no conflicts declared. Rosanna Inzitiari no conflicts declared. Aoife Cotter no conflicts declared. Stefano Savinelli no conflicts declared. Eoin R Feeney has received honoraria and/or travel grants from Gilead Sciences, Abbvie, MSD, Vidacare and ViiV Healthcare. Peter Doran no conflicts declared.
Funding Statement
This work was supported by Science Foundation Ireland [grant number 20/COV/0305] and the European Unions Horizon 2020 Research and Innovation Programme under the Marie Sklodowska Curie [grant number 666010 to W.T.]. Abbott Diagnostics provided the reagents for the antibody reactions. The funding sources had no role in the study design recruitment data collection or analysis of the study results. Representatives from Abbott Diagnostics were provided an opportunity to review and comment on the manuscript prior to submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
1) The Mater Misericordiae University Hospital and Mater Private Hospital Institutional Review Board 2) St. Vincents Healthcare Group Ethics and Medical Research Committee
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos